| scholarly article | Q13442814 |
| P356 | DOI | 10.1196/ANNALS.1423.050 |
| P698 | PubMed publication ID | 17911463 |
| P2093 | author name string | Marcolongo R | |
| Graziani G | |||
| Tognon S | |||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | uveitis | Q280027 |
| P304 | page(s) | 474-484 | |
| P577 | publication date | 2007-09-01 | |
| P1433 | published in | Annals of the New York Academy of Sciences | Q2431664 |
| P1476 | title | Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects | |
| P478 | volume | 1110 |
| Q27687590 | Anti-TNF-alpha therapy and systemic vasculitis |
| Q37782273 | Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease |
| Q44524653 | Behcet's disease--ophthalmological and general aspects: Part 2: Therapy |
| Q37279367 | Behçet's disease: recent advances in early diagnosis and effective treatment |
| Q26829826 | Biologics in uveitis |
| Q37406600 | Current trends in the management of ocular symptoms in Adamantiades-Behçet's disease |
| Q37174386 | Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases |
| Q35699360 | Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients |
| Q34887046 | Emerging role of antioxidants in the protection of uveitis complications. |
| Q37990508 | High dose infliximab in the treatment of refractory uveitis: does dose matter? |
| Q37105146 | Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis |
| Q37712230 | Update on the therapy of Behçet disease |
| Q52899661 | [Anti-TNF-α treatment for uveitis. Analysis of the current situation]. |
Search more.